Navigation Links
EU Drug Regulator Highlights Depression Danger of Weight-loss Pill

The European drug regulator EMEA said Thursday it had maintained authorisation of weight-loss pill Acomplia in the European Union, but had ordered it to be withheld from people suffering from depression.

A panel of experts from the US Food and Drug Administration concluded in June that the dieting treatment, which can also be used to treat diabetes, was unsafe because it caused suicidal thoughts as a side-effect.

The maker of the drug, French group Sanofi-Aventis, abandoned attempts to win approval for the drug in the United States as a result.

The European Medicines Agency (EMEA) recommended Thursday that Acomplia, also known as Rimonabant, should not be given to patients with depression or those taking anti-depressants because of the risk of psychiatric side-effects.

The agency said that depression was known as the main side-effect of the drug and this had been signalled at the time of its approval in June 2006.

However, the Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended upgrading the warning about depression.

Sanofi-Aventis, the fourth-biggest drug maker in the world, announced afterwards that it had changed its labelling to take into account the EMEA's comments.

The recommendation from the EMEA will be sent to doctors prescribing drugs in the countries where the drug in being sold.


Page: 1

Related medicine news :

1. US Regulator Sees No Link Between Tamiflu And Japan Deaths
2. Tumor Suppressor p53s Contradictory Regulatory System
3. A brush with the U.S. Regulators can cost a fortune
4. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
5. Human Complexity Can Be Attributed To Regulatory Sequence
6. Regulators Object Drug Produced from Genetically Engineered Farm Animals
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
10. Drug Regulators Need To Think In Long-Term, Say Charities
11. Regulatory T-cells – Protector or Cause of Diseases
Post Your Comments:

(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
Breaking Medicine Technology: